148 results about "Optic vesicle" patented technology

The invention relates to the formation of peptide / lipid vesicles and complexes through the co-lyophilization of peptides, preferably that are able to adopt an amphipathic alphahelical conformation, and one or more lipids. A single solution which solubilizes both the peptides and lipids or two separate solutions may be lyophilized.

Systems and methods that control the size and composition of emulsified droplets, multi-lamellar and asymmetric vesicles, encapsulation of reagents, membrane proteins, and sorting of vesicles / droplets. More particularly, microfluidic devices for controlled viscous shearing of oil-water emulsions of micro- and nano-scale droplets, the subsequent formation of amphiphilic vesicles such as liposomes, polymer vesicles, micelles, and the like, the post-assembly and post-processing of the droplets including splitting, fusing, sorting and the like, polymer emulsions, and the integration of amphiphilic vesicle production-line on a single microfluidic chip. Preferably, the microfluidic device enables oil-water co-flows with tunable viscous shear forces higher than the immiscible interfacial tension forces that generate favorable conditions for droplet formation.

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

Novel lipid compounds are provided that may be termed "pro-cationic" in that they are neutral or negatively charged until they are either brought into contact with cellular membranes or are internalized by cells. The lipids have a hydrophobic tail group and a hydrophilic head group, the head group incorporating both a positively and negatively charged region at physiological pH. The hydrophobic tail group is stably connected to the positive region of the head group which in turn is connected to the negative region by a disulfide bond that is susceptible to cleavage by membrane-bound and intracellular factors. Cleavage of the disulfide bond removes the negatively charged region from the head group resulting in a lipid that is cationic and therefor fusogenic with negatively charged cell membranes. Consequently, lipids of the invention are useful as components of liposomes that serve as vehicles for delivering pharmaceutical agents into cells with reduced toxicity.

The invention relates to the formation of peptide / lipid vesicles and complexes through the co-lyophilization of peptides, preferably that are able to adopt an amphipathic alphahelical conformation, and one or more lipids. A single solution which solubilizes both the peptides and lipids or two separate solutions may be lyophilized.

The present invention relates to a hollow sphere or porous sphere preparation method through vesicle and multi-chamber vesicle template method. The preparation method is characterized in that a surface active agent forms vesicle and multi-chamber as the soft template under certain conditions; inorganic material carries out nucleus growth on the surface of the soft template so as to copy the shape of the vesicle and multi-chamber vesicle and obtain a single-layer hollow sphere and multi-layer hollow sphere structure; due to different growing ways of crystal, the formed hollow sphere can be single crystal, polycrystal or multiaperture. The surface active agent is anion surface active agent, cation active agent or a mixer of the two surface active agents. The deposited inorganic material includes oxide, sulfide, simple metal substance, selenide, hydroxid or inorganic salts, which form core and grow on the surface of the vesicle and multi-chamber vesicle and finally obtain the single-layer and multi-layer hollow sphere structure and the porous sphere structure. Cu2O and ZnS hollow sphere or porous sphere is taken as the embodiment for detailed description.

Construction and characterization of microfabricated recessed disk microelectrodes (RDMs) of 14 and 55 μm diameter are reported. The work reported here makes several new contributions to the current literature on microfabricated RDMs. Hybrid blamers were constructed by fusion of vesicles of dimyristoylphosphatidyl choline (DMPC), which forms the top layer, with ethanol-rinsed SAMs of hexadecanethiol on gold, which form the bottom layer. Gramicidin A was included in the modifying solutions to incorporate it into hybrid blamers.

Vesicles for delivery of active macromolecules which are formed from amphiphilic segmented copolymers having one or more mucoadhesive groups or regions and which can be used for delivery of an active agent to an area of the body having a mucous membrane, such as but not limited to the gastrointestinal tract.

The present invention provides biocompatible vesicles comprising semi-permeable, thin-walled encapsulating membranes which are formed in an aqueous solution, and which comprise one or more synthetic super-amphiphilic molecules. When at least one super-amphiphile molecule is a block copolymer, the resulting synthetic vesicle is termed a “polymersome.” The synthetic, reactive nature of the amphiphilic composition enables extensive, covalent cross-linking of the membrane, while maintaining semi-permeability. Cross-linking of the polymer building-block components provides mechanical control and long-term stability to the vesicle, thereby also providing a means of controlling the encapsulation or release of materials from the vesicle by modifying the composition of the membrane. Thus, the encapsulating membranes of the present invention are particularly suited for the reliable, durable and controlled transport, delivery and storage of materials.

The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and / or peptides. The nitric oxide and / or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

The present invention generally relates to compositions and methods for topical or transdermal delivery and treatment of wounds and / or promoting wound healing. In some cases, the composition may include nitric oxide and / or peptides. The nitric oxide and / or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., wounded skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

The present invention provides a composite material, preferably an ophthalmic device, more preferably a contact lens, which comprises a vesicle-containing coating including at least one layer of a vesicle and one layer of a polyionic material having charges opposite the charges of the vesicle. Such composite material can find use in biomedical applications, for example, a device for localized drug delivery and an in vivo analyte sensor such as glucose sensing contact lens. By lifting off the vesicle-containing coating from a substrate, a self-standing membrane (film) capable of encapsulating a wide variety of guest materials can be prepared. In addition, the invention provides methods for making vesicle-containing composite and film materials of the present invention.

An amphiphilic compound is provided capable of forming vesicles or liposomes, said amphiphilic compound having at least one headgroup containing a selectively cleavable group or moiety such as a residue of a choline or phenylalanine derivative, and at least one hydrogen-bonding group located either within said headgroup and / or in close proximity thereto. The cleavable group or moiety is cleaved under selective conditions including change of chemical, physical or biological environment and is preferably cleaved enzymatically in a biological environment such as the brain or the blood. Vesicles or liposomes made from said amphiphilic compounds are suitable for delivery of a therapeutic substance or a diagnostic agent specifically to a target organ or tissue, or for delivery of a nucleic acid for gene therapy.

A liposome composition for localizing an anti-tumor compound to a solid tumor via the bloodstream. The liposomes, which contain the agent in entrapped form, are composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer, and have sizes in a selected size range between 0.07 and 0.12 microns. After intravenous administration, the liposomes are taken up by the tumor within 24-48 hours, for site-specific release of entrapped compound into the tumor. In one composition for use in treating a solid tumor, the compound is an anthracycline antibiotic drug which is entrapped in the liposomes at a concentration of greater than about 50 mug agent / mumole liposome lipid. The method results in regression of solid colon and breast carcinomas which are refractory to anthracycline antibiotic drugs administered in free form or entrapped in conventional liposomes.

Novel targeted compositions which may be used for diagnostic and therapeutic use. The compositions may comprise lipid, protein or polymer gas-filled vesicles which further comprise novel compounds of the general formula L-P-T, wherein L comprises a hydrophobic compound, P comprises a hydrophilic polymer, and T comprises a targeting ligand which targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The compositions can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.

The invention discloses vesicles consisting of amphiphilic polymer and application of the vesicles. A main chain of the amphiphilic polymer consists of a hydrophilic chain segment and a biodegradable hydrophobic chain segment, wherein the molecular weight of the hydrophilic chain segment is 4 to 6kDa; the molecular weight of the hydrophobic chain segment is 3 to 5 times that of the hydrophilic chain segment; the hydrophobic chain segment is formed by performing random copolymerization on a monomer A and a monomer B in a molar ratio of (5-20):1; the monomer A is trimethylene carbonate or cyclic carbonate; the monomer B is acrylate-based carbonate or vinyl sulfone-based carbonate; the hydrophobic chain segment is grafted with a short branched chain; the grafting position is a double bond of the monomer B; a monomer forming the short branched chain is 3-mercaptopropionic acid, cysteamine hydrochloride or cysteine; and the grafting rate is 0.3 to 1. The vesicles are directly prepared from the amphiphilic polymer in an aqueous solution and used as a carrier and a release system of a protein medicine, the encapsulating efficiency and bioavailability of the protein medicine can be improved, and the stability of the encapsulated protein is enhanced.

Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions, such as liposomes and other lipid vesicles, to the tympanic membrane. Medicaments useful for treating pain, inflammation or infection in the outer ear may be co-administered. If utilized for transmembrane administration, the liposomes or other lipid vesicles will usually not be sterically stabilized. The medicaments delivered according to the methods of the invention include antibiotic, anti-viral, anti-fungal and anti-inflammatory agents that are useful in treatment and / or prophylaxis of middle ear infections and their sequelae.

The invention pertains to the field of pharmaceutical technology, which more particularly relates to an elastic nano-vesicle carrier which can transport the active ingredients of the drug to penetrate the natural permeability barrier or pores (such as skin, mucosa, and organs, etc.) and the preparation method, as well as the usage. The vesicle has lipid double molecular layers for transporting one or more active ingredients to penetrate the natural barrier. The vesicle at least contains three dressing components of phospholipid, membrane softener and alcohol, and the three have different physical and chemical properties. The diameter of the typical nano-vesicle is less than 200nm. The vesicle carrier containing the active ingredients of the drug can be applied in the injection, spray and the transdermal preparation.

It is an object of the present invention to provide an enzyme preparation which is excellent in stability in blood (blood residence) and in transfer to a target organ (targeting property), and can be used effectively in enzyme replacement therapy or the like.This problem is solved by a lipid vesicle composition wherein vesicles composed of a lipid bilayer membrane are encapsulating an enzyme, the composition being capable of retaining stably the activity of the enzyme even outside the stable pH range of the enzyme.

The present invention provides compositions of yeast extracellular vesicles comprising biologically active molecules, methods for making the same, and methods for the use of the yeast extracellular vesicles to deliver biologically active molecules to target cells. In addition, the invention provides cells and compositions comprising the biologically active molecules and vesicles, which can be used as transfection reagents. The invention further provides methods for producing said compositions of biologically active molecules with vesicles as well as the cells that produce those compositions. Compositions and methods for delivering biologically active molecules, such as a small molecule, a DNA expression plasmid, an RNA molecule, a peptide, or a protein, to cells and / or tissues are provided. The compositions and cells are useful, for example, in delivering biologically active RNA molecules to cells to modulate target gene expression in the diagnosis, prevention, amelioration, and / or treatment of diseases, disorders, or conditions in a subject or organism.

Aspects of the invention provide hollow nanoparticles and uses thereof. In particular, the invention provides membrane-enclosed vesicles comprising a truncated form of an HBsAg S protein lacking one or two of its amino-terminal transmembrane domains.

The invention discloses arginine hybrid cell-penetrating peptide and application thereof, belonging to the field of biological molecule. The cell-penetrating peptide is prepared by hybrid construction from non-natural D-arginine (r) and natural L-arginine (R) and has a structure of (r) n (R) m, wherein r and R can be randomly arranged in the structure, n and m are the number of amino acid residues, the sum of n and m is greater than or equal to 4 and less than or equal to 12, n is greater than or equal to 1 and less than or equal to 11, and m is greater than or equal to 1 and less than or equal to 11; and the N end and the C end of the cell-penetrating peptide can be singly or simultaneously connected with different markers or cargo molecules and carry the markers and the cargo molecules into cells. The cell-penetrating peptide can carry the markers and the cargo molecules into the cells with high efficiency and low cytotoxicity, simultaneously has very strong enzymolysis resistant and serum degradation resistant capacities, and can escape from vesicles corpuscles after entering the cells.

The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally downregulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.

The invention provides a cross-linked biologically degradable carrier polymer, a micelle and a vesicle, and a preparation method and an application of the cross-linked biologically degradable carrier polymer, micelle and vesicle, belonging to the field of biological medical material and solving a poor stability problem of the existing polymer micelle and vesicle. The carrier polymer is an A-B-C tri-block polymer, wherein the block A is polyethylene glycol, the block B is the polyethylene glycol containing functional groups in a lateral chain, and the block C is biologically degradable polyester. The invention also provides the polymer micelle and vesicle, which is formed by self assembly of the carrier polymer, wherein the size of the polymer micelle is 20-1000nm, and the size distribution is 0.01-0.50; the size of the vesicle is 20-1000nm, and the size distribution is 0.01-0.50. The polymer micelle provided by the invention can package fat-soluble matters; and the polymer vesicle canpackage water-soluble matters and the fat-soluble matters at the same time; and the polymer micelle or the vesicle has better mechanical strength and stability because the polymer micelle or the vesicle contains a transitional layer formed by the cross-linked block B.

Nanoparticles containing nucleic acid and suitable for use as in vivo delivery agents for nucleic acids are provided. The nanoparticles use a covalent conjugate of a polycation such as polyethylenimine and phospholipids. The final DNA-containing nanoparticle has a vesicular structure with a polyplex core surrounded by a mixed lipid / PEG-lipid monolayer envelope and offers simple preparation, high loading capacity, and in vivo stability. The nanoparticles have good in vivo stability and a prolonged blood circulation time and can effectively deliver a gene to a biological target such as a tumor.

The invention pertains to the technical field of porous material, in particular to a dioxide vesicle material with a controllable shape, a controllable size and a controllable wall thickness and a preparation method thereof. The invention adopts a sol-gel method to synthetize novel silicon dioxide vesicle material with the controllable shape, an adjustable aperture and an alterable wall thickness in a near-neutral aqueous solution system. The preparation method comprises the steps such as collaborative self-assembly, hydrothermal treatment, drying, roasting to remove a template agent, etc. of the sol-gel process of vesicle with various patterns. The reaction conditions of the invention are mild, the operation is simple and easy and the material structure is rich and controllable. The shape, the size, the wall thickness, etc. of the material can be effectively adjusted and controlled by changing the conditions of the ratio of silicon sources and a surface active agent and the mol ratio of different silicon sources and by adjusting the mass ratio of composing different polymers, etc. The vesicle material has wide applicable prospect in the fields of adsorption, catalyst carriers, slow release of drug, separation, chromatogram, paints, micro reactors, etc.

Engineered exosomes for the delivery of bioactive cargo are provided. The exosomes incorporate a tetraspanin transmembrane anchoring scaffold onto the membrane of the exosome. The tetraspanin transmembrane anchoring scaffold has a C-terminal attachment site in the inner-vesicle space of the exosome, a N-terminal attachment site in the inner-vesicle space or the outer-vesicle space, and / or a loop attachment site in the outer-vesicle space. Peptides can be attached to the different attachments sites in any form or combination. Tetrapanins naturally anchor on the exosome membrane, are biocompatible, and allow for robust loading and delivery of bioactive cargos in mammalian system.

The invention relates to the technical field of biological separation and extraction, in particular to an extracting method of extracellular vesicles. The method comprises the steps that a biologicalsample is provided; the biological sample is in contact with a capturing surface at least twice on the condition that impurities in the biological sample are partially or wholly reserved on the capturing surface, wherein the impurities are partial or whole other substances except the extracellular vesicles in the biological sample, and the capturing surface comprises an inner surface and / or outersurface of a spherical-particle porous material; when the impurities are partially or wholly reserved on the surface of a capture, breakthrough liquid is extracted liquid containing the extracellularvesicles; or the breakthrough liquid is further concentrated. By means of the method, the epicyte vesicles can be quickly separated and purified, the separation operation is simple, the single use cost is low, the separated sample in high in purity, the bioactivity of the sample is kept good, and the extracting method is applied to fundamental research in the aspects of biomarker discovery, biotherapy and the like and industrial production.